Filing Analysis
CervoMed Inc. announced positive data from its Phase 2b RewinD-LB trial of neflamapimod for the treatment of dementia with Lewy bodies (DLB). The data, presented at the 2026 American Academy of Neurology Annual Meeting, showed the drug increased basal forebrain volume and functional connectivity.
Key Facts
- The data was presented at the 2026 American Academy of Neurology (AAN) Annual Meeting on April 22, 2026.
- The Phase 2b RewinD-LB trial evaluated neflamapimod in patients with dementia with Lewy bodies.
- Results demonstrated that neflamapimod increased basal forebrain volume and functional connectivity.
- The company has updated its investor presentation on its website to include these clinical findings.
CervoMed Inc. announced that it will present key aspects of its neflamapimod clinical program at the 2026 Lewy Body Dementia Association Annual Meeting. The presentation is scheduled for April 7, 2026, in Atlanta, GA.
Key Facts
- The company is presenting at the 2026 Lewy Body Dementia Association Annual Meeting on April 7, 2026.
- The presentation focuses on the neflamapimod clinical program.
- The disclosure was made under Item 7.01 (Regulation FD Disclosure).
- A press release regarding the presentation was included as Exhibit 99.1.
CervoMed Inc. announced the availability of an updated investor presentation on its website covering business operations, clinical studies, and financial position. The company intends to use this presentation for upcoming conferences and meetings with analysts and investors.
Key Facts
- Filing date: March 23, 2026.
- Item 7.01 (Regulation FD Disclosure) used to announce updated investor materials.
- Presentation includes information on clinical studies, development plans, and financial position.
- Materials are hosted on the company's website under the 'Investors – Events and Presentations' section.
CervoMed Inc. announced new analyses from its Phase 2b RewinD-LB clinical trial of neflamapimod in patients with dementia with Lewy bodies. The findings, which include stratified data by plasma pTau181 levels and PK/PD analyses, will be presented at the AD/PD 2026 Conference on March 21, 2026.
Key Facts
- The company is presenting data at the AD/PD 2026 Conference in Copenhagen, Denmark.
- Analyses focus on the Phase 2b RewinD-LB clinical trial of neflamapimod for dementia with Lewy bodies (DLB).
- New data suggests a greater treatment effect in patients with a reduced likelihood of Alzheimer's (AD) co-pathology, identified via plasma pTau181 subsets.
- The filing includes new PK/PD (pharmacokinetic/pharmacodynamic) analyses of the Phase 2b data.
CervoMed Inc. announced its financial results for the fourth quarter and full year ended December 31, 2025, and updated its investor presentation materials.
Key Facts
- Financial results for the quarter and full year ended December 31, 2025, were released on March 17, 2026.
- The company updated its investor presentation on its website under the 'Investors – Events and Presentations' section.
- The information in the filing was furnished under Items 2.02 and 7.01, which are not deemed 'filed' for purposes of Section 18 of the Exchange Act.
- The filing includes Exhibit 99.1, the press release detailing the financial results.
CervoMed announced the successful completion of a Phase 1 study evaluating the pharmacokinetics of a new crystal form of its lead drug candidate, neflamapimod. The company also provided updates regarding its upcoming Phase 3 trial for dementia with Lewy bodies (DLB).
Key Facts
- Successfully completed a Phase 1 healthy volunteer study for a new, stable crystal form of neflamapimod
- The study evaluated the pharmacokinetics of the drug product
- Provided updates regarding the planned Phase 3 trial in dementia with Lewy bodies (DLB)
- Information was disclosed via a press release and an updated investor presentation on March 4, 2026